Transgenic Mice Demonstrate AP-1 (activator Protein-1) Transactivation is Required for Tumor Promotion
Overview
Affiliations
Activator protein-1 (AP-1) is a transcription factor that consists of either a Jun-Jun homodimer or a Jun-Fos heterodimer. Transactivation of AP-1 is required for tumor promoter-induced transformation in mouse epidermal JB6 cells and for progression in mouse and human keratinocytes. Until now, the question of whether AP-1 transactivation is required for carcinogenesis in vivo has remained unanswered, as has the issue of functionally significant target genes. To address these issues we have generated a transgenic mouse in which transactivation mutant c-jun (TAM67), under the control of the human keratin-14 promoter, is expressed specifically in the basal cells of the epidermis where tumor induction is initiated. The keratin-14-TAM67 transgene was expressed in the epidermis, tongue, and cervix, with no apparent abnormalities in any tissue or organ. TAM67 expression blocked 12-O-tetradecanoylphorbol 13-acetate (TPA, phorbol 12-tetradecanoate 13-acetate) induction of the AP-1-regulated luciferase in AP-1 luciferase/TAM67 mice, but did not inhibit induction of candidate AP-1 target genes, collagenase-1 or stromelysin-3. More interestingly, TAM67 expression did not inhibit TPA-induced hyperproliferation. In two-stage skin carcinogenesis experiments, the transgenic animals showed a dramatic inhibition of papilloma induction. We conclude that transactivation of a subset of AP-1-dependent genes is required for tumor promotion and may be targeted for cancer prevention.
Vitamin A resolves lineage plasticity to orchestrate stem cell lineage choices.
Tierney M, Polak L, Yang Y, Abdusselamoglu M, Baek I, Stewart K Science. 2024; 383(6687):eadi7342.
PMID: 38452090 PMC: 11177320. DOI: 10.1126/science.adi7342.
Yang C, Rybchyn M, De Silva W, Matthews J, Dixon K, Holland A Int J Mol Sci. 2023; 24(5).
PMID: 36902353 PMC: 10002576. DOI: 10.3390/ijms24054921.
The Use of Retinoids for the Prevention and Treatment of Skin Cancers: An Updated Review.
Ramchatesingh B, Martinez Villarreal A, Arcuri D, Lagace F, Setah S, Touma F Int J Mol Sci. 2022; 23(20).
PMID: 36293471 PMC: 9603842. DOI: 10.3390/ijms232012622.
Synthetic lethal kinases in Ras/p53 mutant squamous cell carcinoma.
Moser R, Gurley K, Nikolova O, Qin G, Joshi R, Mendez E Oncogene. 2022; 41(24):3355-3369.
PMID: 35538224 DOI: 10.1038/s41388-022-02330-w.
The Fra-1/AP-1 Oncoprotein: From the "Undruggable" Transcription Factor to Therapeutic Targeting.
Casalino L, Talotta F, Cimmino A, Verde P Cancers (Basel). 2022; 14(6).
PMID: 35326630 PMC: 8946526. DOI: 10.3390/cancers14061480.